Experts spotlight the prostate and bladder cancer presentations they're most excited to see at the 2026 ESMO Congress.
Opinion|Videos|January 30, 2024
The result of the phase 3 CHECKMATE 901 trial which looked at Nivolumab plus gemcitabine-cisplatin versus gemcitabine-cisplatin alone for previously untreated unresectable or metastatic urothelial carcinoma
Author(s)Guru P. Sonpavde, MD
Dr. Sonpavde discusses the efficacy and safety findings from this randomized, open-label trial enrolling patients with advanced or metastatic urothelial carcinoma who had not received prior systemic chemotherapy.
Advertisement
Advertisement
Related to this article
Updated ARC-20 data showed casdatifan activity as monotherapy and in combinations across treatment lines in advanced clear cell RCC.
The FDA accepted an NDA for UGN-103 for recurrent low-grade intermediate-risk NMIBC, with a target action date of June 14, 2027.
The FDA expands nogapendekin alfa inbakicept in bladder cancer, European regulators back daraxonrasib in pancreatic cancer, and more.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Patients with resected RCC given adjuvant durvalumab with or without tremelimumab described persistent low-grade toxicities as most disruptive to QOL.
The FDA approved nogapendekin alfa inbakicept plus BCG for BCG-unresponsive NMIBC with high-grade papillary-only tumors.
First-line IO-based combination regimens were increasingly used and associated with longer observed survival in advanced renal cell carcinoma.
Advertisement
Advertisement
Trending on OncLive
1
Dr Cercek on the FDA Approval of Dostarlimab for dMMR/MSI-H Locally Advanced Rectal Cancer
2
Vilamakitug Meets OS Threshold in Phase 1/2 Refractory mCRC Trial
3
Weigh Benefit Against Burden: Defining Lurbinectedin’s Role in a Shifting Small Cell Lung Cancer Landscape
4
Dr Warren on the Goal of the 4WARD Trial Evaluating Mavorixafor in Chronic Neutropenia
5